UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
January
5, 2009
(Date of
Earliest Event Reported)
Advaxis,
Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
00028489
|
02-0563870
|
(State or other
jurisdiction
|
(Commission
|
(IRS
Employer
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
Technology
Centre of New Jersey
675
Rt. 1, Suite B113
North
Brunswick, N.J. 08902
(Address
of principal executive offices)
(732) 545-1590 (Registrant’s
telephone number, including area code)
|
(Former name or former address,
if changed since last
report.)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events
On
January 6, 2009, Advaxis, Inc issued a press release regarding its Phase II
Clinical Trail “Hold” Lifted.
A
copy of the press release is attached as Exhibit 99.1 to this Current Report and
is incorporated herein by this reference.
Item
9.01 Financial Statements and
Exhibits
99.1
|
Advaxis,
Inc. press release, dated January 6,
2009
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Dated:
January 6, 2009
|
Advaxis,
Inc.
|
|
|
|
By:
|
/s/
Thomas A. Moore
|
|
Name:
|
Thomas
A. Moore
|
|
Title:
|
Chief
Executive Officer
|